2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice …
FLJ Visseren, F Mach, YM Smulders… - European heart …, 2021 - academic.oup.com
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
[HTML][HTML] Semaglutide in patients with heart failure with preserved ejection fraction and obesity
MN Kosiborod, SZ Abildstrøm, BA Borlaug… - … England Journal of …, 2023 - Mass Medical Soc
Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …
associated with a high symptom burden and functional impairment, especially in persons …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
ME Nassif, SL Windsor, BA Borlaug, DW Kitzman… - Nature medicine, 2021 - nature.com
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of
symptoms and functional limitations, and have a poor quality of life. By targeting …
symptoms and functional limitations, and have a poor quality of life. By targeting …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: the Task Force on sports cardiology and exercise in patients with …
or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …
whatsoever the individual responsibility of health professionals to make appropriate and …
[HTML][HTML] Physical rehabilitation for older patients hospitalized for heart failure
DW Kitzman, DJ Whellan, P Duncan… - … England Journal of …, 2021 - Mass Medical Soc
Background Older patients who are hospitalized for acute decompensated heart failure have
high rates of physical frailty, poor quality of life, delayed recovery, and frequent …
high rates of physical frailty, poor quality of life, delayed recovery, and frequent …
Heart failure with reduced ejection fraction: a review
Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …
Sedentary behavior, exercise, and cardiovascular health
Sedentary behavior and physical inactivity are among the leading modifiable risk factors
worldwide for cardiovascular disease and all-cause mortality. The promotion of physical …
worldwide for cardiovascular disease and all-cause mortality. The promotion of physical …